Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michelle Miller

Nurse Practitioner, Psychiatric/Mental Health Pendleton, SC Nurse Practitioner

NPI 1447857925 CMS profile 11075545

158 E Main St, Pendleton, SC 29670

Open in the dashboard

General payments

$4,468

322 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Miller of Pendleton, SC is reported in the CMS Open Payments database as having received $4,468 across 322 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $141 8
2024 General $981 72
2023 General $1,317 85
2022 General $989 82
2021 General $1,040 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Miller
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Michelle Miller were reported at $141. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Michelle Miller Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,040 $166 $54–$482 $132
2022 $989 $195 $66–$559 $149
2023 $1,317 $233 $82–$673 $160
2024 $981 $236 $84–$688 $164
2025 $141 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $969 93 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $450 38 payments
  3. Otsuka America Pharmaceutical, Inc. $386 27 payments
  4. ITI, Inc. $309 18 payments
  5. Supernus Pharmaceuticals, Inc. $266 16 payments
  6. Janssen Pharmaceuticals, Inc $266 13 payments
  7. Corium, Inc. $256 24 payments
  8. Vanda Pharmaceuticals Inc. $220 13 payments
  9. Tris Pharma Inc $199 9 payments
  10. Neurocrine Biosciences, Inc. $152 9 payments
  11. Other $994 62 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,346 320 payments
  2. Education $122 2 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $941 91 payments
  2. TRINTELLIX $450 38 payments
  3. CAPLYTA $309 18 payments
  4. REXULTI $300 21 payments
  5. Azstarys $256 24 payments
  6. HETLIOZ $220 13 payments
  7. FANAPT $220 13 payments
  8. INVEGA SUSTENNA $216 10 payments
  9. Dyanavel XR $199 9 payments
  10. Qelbree $192 12 payments
  11. Other $2,084 127 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

985

Median for Nurse Practitioner: 389

Drug cost

$233,685

Median for Nurse Practitioner: $21,885

Branded share of claims

18%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 13 $109,747
Vraylar Cariprazine Hcl Brand 28 $41,143
Fanapt Iloperidone Brand 13 $26,401
Caplyta Lumateperone Tosylate Brand 12 $21,376
Nuedexta Dextromethorphan Hbr/Quinidine Brand 13 $20,128
Belsomra Suvorexant Brand 12 $5,033
Tizanidine Hcl Generic 12 $1,227
Aripiprazole Generic 29 $895
Quetiapine Fumarate Generic 63 $582
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 20 $573

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$10,281

Medicare's payments for the services billed

Medicare patients

19

Average age 67

Services billed

190

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 68%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $180
$180 28 —
Qelbree
  • Supernus Pharmaceuticals, Inc. $171
$171 — —
Azstarys
  • Corium, Inc. $161
$161 — —
Dyanavel XR
  • Tris Pharma Inc $61
$61 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $56
$56 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

322 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record